This MedLibrary.org supplementary page on Felbamate is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Felbamate
|
|
| Systematic (IUPAC) name | |
| trideca-1,3,11-trien-5,7,9-triyne | |
| Identifiers | |
| CAS number | |
| ATC code | N03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C11H14N2O4 |
| Mol. mass | 238.24 |
| Pharmacokinetic data | |
| Bioavailability | > 90% |
| Metabolism | Hepatic |
| Half life | 20-23 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C (USA) |
| Legal status |
Unscheduled |
| Routes | Oral |
Felbamate (marketed under the brand name Felbatol by MedPointe) is an anticonvulsant drug used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. However, an increased risk of potentially fatal aplastic anemia and/or liver failure limit the drugs usage to severe refractory epilepsy.
Contents |
Mechanism of action
As with most anticonvulsants, the precise mechanism is unknown. It has a weak inhibitory effect on GABA receptor binding sites.
It may also work as a NMDA receptor antagonist.[1]
Approval history
United States
- August 1993. Felbamate was approved for partial seizures with and without secondary generalization in adults and for Lennox-Gastaut Syndrome, a serious form of childhood epilepsy. Over the following year 150,000 people were started on felbamate therapy and a third of these became established.
- August 1, 1994. It was urgently withdrawn [1] after 10 cases of aplastic anemia. A "Dear Doctor" letter was sent to 240,000 physicians.
- September 27, 1994. Felbamate had a limited redemption in another "Dear Doctor" letter sent to 260,000 physicians. It was recommended that the drug remain available only for patients with severe epilepsy for whom the benefits outweigh the risks, and that changes be made to the product's labelling to reflect the newly recognized risk [2]. This redemption came with an additional warning since there had been 10 cases acute liver failure (4 of which were fatal). At this point, 10,000 to 12,000 people remained on the drug.
United Kingdom
- The drug is only available on a limited named-patient basis.
Indications and usage
- Adults: Monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization.
- Children: Adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome.
Dosing
Felbamate is available in tablets (400 mg and 600 mg) and as a peach-coloured oral suspension (600 mg/5 mL).
- Adults (> 14 years): begin with 1,200 mg daily given every 6 to 8 hours
- Children (2 > 14 years): 15 to 45 mg per kg per day given every 6 to 8 hours
Side effects
Adverse reactions include decreased appetite, vomiting, insomnia, nausea, dizziness, somnolence, and headache. Many patients report increased alertness with the drug. Two rare but very serious effects include aplastic anemia and hepatic (liver) failure. The risk of aplastic anemia is between 1:3,600 and 1:5,000, of which 30% of cases are fatal. The risk of hepatic failure is between 1:24,000 to 1:34,000, of which 40% of cases are fatal.
Drug interactions
Felbamate interacts with other AEDs, the dose of which may be reduced in order to avoid adverse effects.
References
- Leppik IE, Dreifuss FE, Pledger GW, Graves NM, Santilli N, Drury I, Tsay JY, Jacobs MP, Bertram E, Cereghino JJ, et al.
- [Abstract]. Neurology. 1991 Nov;41(11):1785–9.
- Felbatol: Prescribing Information
- RxList: Felbamate contains extensive information including the patient warning and a sample consent form.
- Hard Choices with Felbamate
- Newer Antiepileptic Drugs: Gabapentin, Lamotrigine, Felbamate, Topiramate and Fosphenytoin
External links
|
|||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 12 September 2008, at 17:51.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Felbamate".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.